MedTrace Logo

Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets

NCT06154434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-12-08

No results posted yet for this study

Summary

This clinical study is an open label, randomized, fasting condition, single-dose, two-period crossover study to compare the bioequivalence of Chlorpromazine HCl 100mg Tablets after oral administration in healthy subjects.

Conditions

  • Healthy Subject

Interventions

DRUG

Chlorpromazine HCl 100mg Tablets

single-dose administered after a 10-hour overnight fast.

Sponsors & Collaborators

  • Whanin Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • MINGYU PARK · Chungbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-06
Primary Completion
2019-02-12
Completion
2019-02-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06154434 on ClinicalTrials.gov